Clinical Performance of Three Commercial SARS-CoV-2 Rapid Antigen Tests for Community-Dwelling Individuals in a Tropical Setting열대 환경에서 커뮤니티 거주 개인을 위한 3가지 상용 SARS-CoV-2 신속 항원 검사의 임상 성능Multicenter Study Published on 2022-07-052022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] analytical sensitivity Antigen antigen test biosensor carried Certest clinical clinical performance. Clinical use country COVID-19 pandemic cross-reactivity detect Ecuador genomic Genomic surveillance gold gold standard IMPROVE individual individuals infectious agent International Laboratory limit of detection market multicenter Mutation Nasopharyngeal swab nasopharyngeal swabs new SARS-CoV-2 performance point of care positive prevalent Rapid RapiGEN RapiGEN® Ag test kit reduction in regulatory agencies RT-qPCR SARS-CoV-2 SARS-CoV-2 detection SARS-CoV-2 surveillance SARS-CoV-2 transmission SARS-CoV-2 variants SARS–CoV–2 SD-Biosensor sensitivity setting shown South America South Korea Spain specificity Surveillance symptomatic individuals Test tested tropical variant [DOI] 10.3389/fcimb.2022.832235 PMC 바로가기 [Article Type] Multicenter Study